Biotechnology
Compare Stocks
2 / 10Stock Comparison
ALMS vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ALMS vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.00B | $656M |
| Revenue (TTM) | $22M | $263M |
| Net Income (TTM) | $-245M | $-81M |
| Gross Margin | 96.3% | 99.5% |
| Operating Margin | -20.6% | -44.0% |
| Total Debt | $37M | $9M |
| Cash & Equiv. | $90M | $143M |
ALMS vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 24 | May 26 | Return |
|---|---|---|---|
| Alumis Inc. Common … (ALMS) | 100 | 191.7 | +91.7% |
| Arvinas, Inc. (ARVN) | 100 | 38.5 | -61.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALMS vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ALMS is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 72.4%
- 91.7% 10Y total return vs ARVN's -36.1%
- +486.2% vs ARVN's +47.6%
ARVN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.15
- Lower volatility, beta 1.15, Low D/E 2.0%, current ratio 4.92x
- Beta 1.15, current ratio 4.92x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -0.3% revenue growth vs ALMS's -2.5% | |
| Quality / Margins | -30.8% margin vs ALMS's -11.1% | |
| Stability / Safety | Beta 1.15 vs ALMS's 1.77, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +486.2% vs ARVN's +47.6% | |
| Efficiency (ROA) | -9.3% ROA vs ALMS's -57.6%, ROIC -22.4% vs -184.1% |
ALMS vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ALMS vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ARVN leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARVN is the larger business by revenue, generating $263M annually — 11.9x ALMS's $22M. Profitability is closely matched — net margins range from -30.8% (ARVN) to -11.1% (ALMS).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $22M | $263M |
| EBITDAEarnings before interest/tax | -$453M | -$111M |
| Net IncomeAfter-tax profit | -$245M | -$81M |
| Free Cash FlowCash after capex | -$373M | -$276M |
| Gross MarginGross profit ÷ Revenue | +96.3% | +99.5% |
| Operating MarginEBIT ÷ Revenue | -20.6% | -44.0% |
| Net MarginNet income ÷ Revenue | -11.1% | -30.8% |
| FCF MarginFCF ÷ Revenue | -16.9% | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.7% | -65.1% |
Valuation Metrics
ARVN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.0B | $656M |
| Enterprise ValueMkt cap + debt − cash | $2.9B | $522M |
| Trailing P/EPrice ÷ TTM EPS | -8.92x | -8.02x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 124.59x | 2.50x |
| Price / BookPrice ÷ Book value/share | 71.96x | 1.53x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ARVN leads this category, winning 8 of 8 comparable metrics.
Profitability & Efficiency
ARVN delivers a -14.3% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-76 for ALMS. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALMS's 0.12x. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs ALMS's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -75.5% | -14.3% |
| ROA (TTM)Return on assets | -57.6% | -9.3% |
| ROICReturn on invested capital | -184.1% | -22.4% |
| ROCEReturn on capital employed | -144.4% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.12x | 0.02x |
| Net DebtTotal debt minus cash | -$53M | -$134M |
| Cash & Equiv.Liquid assets | $90M | $143M |
| Total DebtShort + long-term debt | $37M | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
ALMS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALMS five years ago would be worth $19,173 today (with dividends reinvested), compared to $1,625 for ARVN. Over the past 12 months, ALMS leads with a +486.2% total return vs ARVN's +47.6%. The 3-year compound annual growth rate (CAGR) favors ALMS at 24.2% vs ARVN's -25.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +184.8% | -10.5% |
| 1-Year ReturnPast 12 months | +486.2% | +47.6% |
| 3-Year ReturnCumulative with dividends | +91.7% | -58.4% |
| 5-Year ReturnCumulative with dividends | +91.7% | -83.8% |
| 10-Year ReturnCumulative with dividends | +91.7% | -36.1% |
| CAGR (3Y)Annualised 3-year return | +24.2% | -25.4% |
Risk & Volatility
Evenly matched — ALMS and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARVN is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than ALMS's 1.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALMS currently trades 83.3% from its 52-week high vs ARVN's 70.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.77x | 1.15x |
| 52-Week HighHighest price in past year | $30.60 | $14.51 |
| 52-Week LowLowest price in past year | $2.76 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +83.3% | +70.7% |
| RSI (14)Momentum oscillator 0–100 | 57.8 | 47.4 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 820K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALMS as "Buy" and ARVN as "Buy". Consensus price targets imply 50.7% upside for ALMS (target: $38) vs 26.7% for ARVN (target: $13).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $38.44 | $13.00 |
| # AnalystsCovering analysts | 8 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.0% |
ARVN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ALMS leads in 1 (Total Returns). 1 tied.
ALMS vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ALMS or ARVN a better buy right now?
Analysts rate Alumis Inc.
Common Stock (ALMS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALMS or ARVN?
Over the past 5 years, Alumis Inc.
Common Stock (ALMS) delivered a total return of +91. 7%, compared to -83. 8% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: ALMS returned +91. 7% versus ARVN's -36. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALMS or ARVN?
By beta (market sensitivity over 5 years), Arvinas, Inc.
(ARVN) is the lower-risk stock at 1. 15β versus Alumis Inc. Common Stock's 1. 77β — meaning ALMS is approximately 54% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 12% for Alumis Inc. Common Stock — giving it more financial flexibility in a downturn.
04Which is growing faster — ALMS or ARVN?
On earnings-per-share growth, the picture is similar: Alumis Inc.
Common Stock grew EPS 72. 4% year-over-year, compared to 53. 8% for Arvinas, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALMS or ARVN?
Arvinas, Inc.
(ARVN) is the more profitable company, earning -30. 8% net margin versus -1011. 7% for Alumis Inc. Common Stock — meaning it keeps -30. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARVN leads at -43. 8% versus -1886. 9% for ALMS. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ALMS or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ALMS or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Arvinas, Inc.
(ARVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15)). Alumis Inc. Common Stock (ALMS) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARVN: -36. 1%, ALMS: +91. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ALMS and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.